FDA Clearance Tracker · K203248
Albumin BCG2
Last checked: Nov 20, 2026Latest source record: Nov 23, 2021 (this decision)Source: openFDAMethods & limitations
Decided
Nov 23, 2021
Substantially Equivalent
Time to decision
384 days
Received Nov 4, 2020. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K203248
- Device name
- Albumin BCG2
- Applicant
- Abbott Ireland Diagnostics Division
- Applicant location
- Longford, IE
- Received
- Nov 4, 2020
- Decided
- Nov 23, 2021
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device type
- Bromcresol Green Dye-Binding, Albumin (CIX)
- Device class
- Class II
- Regulation
- 21 CFR 862.1035
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code CIX. The earliest in FDA's data is K760355, decided Oct 5, 1976.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K203248
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Abbott Ireland Diagnostics Division
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Alkaline Phosphatase2510(k)
K223317 · Decided Jul 21, 2023 · 266 days after receipt
Device type: Nitrophenylphosphate, Alkaline Phosphatase Or Isoenzymes (CJE) · Laboratory Medicine & Pathology
- Total Bilirubin2510(k)
K223324 · Decided Dec 29, 2022 · 59 days after receipt
Device type: Diazo Colorimetry, Bilirubin (CIG) · Laboratory Medicine & Pathology
- Cholesterol2510(k)
K203597 · Decided Jun 30, 2022 · 568 days after receipt
Device type: Enzymatic Esterase--Oxidase, Cholesterol (CHH) · Laboratory Medicine & Pathology
4 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.